Douglas Brown

发表

Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors.

B. Blagg, J. Holzbeierlein, R. Matts, 2013, Assay and drug development technologies.

Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors.

B. Blagg, J. Holzbeierlein, Douglas Brown, 2014, Bioorganic & medicinal chemistry.

Triazole Containing Novobiocin and Biphenyl Amides as Hsp90 C-Terminal Inhibitors.

J. Hall, B. Blagg, C. Subramanian, 2014, MedChemComm.

Alkoxyquinoline O-dealkylation: A new fluorimetric assay for hydrocarbon-induced cytochrome P450 in fish

D. Houlihan, R. Mayer, Douglas Brown, 1995 .

Efficacious cyclic N-acyl O-amino phenol duocarmycin prodrugs.

Katharine K. Duncan, D. Boger, Douglas Brown, 2013, Journal of medicinal chemistry.

Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents.

B. Blagg, J. Holzbeierlein, R. Rajewski, 2011, Journal of medicinal chemistry.

Synthesis of Polyhydroxybenzene Derivatives for Evaluation as Antitumor Agents

Douglas Brown, 1986 .

KU675, a Concomitant Heat-Shock Protein Inhibitor of Hsp90 and Hsc70 that Manifests Isoform Selectivity for Hsp90α in Prostate Cancer Cells

B. Blagg, J. Holzbeierlein, Suman Ghosh, 2015, Molecular Pharmacology.

KU 675 , a Concomitant Heat-Shock Protein Inhibitor of Hsp 90 and Hsc 70 that Manifests Isoform Selectivity for Hsp 90 a in Prostate Cancer Cells s

B. Blagg, J. Holzbeierlein, Suman Ghosh, 2015 .

Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents.

B. Blagg, J. Holzbeierlein, R. Rajewski, 2011, Journal of Medicinal Chemistry.